Artisan International Small-Mid Fund on Genmab A/S
Thesis
Genmab is a vertically integrated pharmaceutical company specialising in antibody therapeutics for cancer. Better-than-expected second-quarter results were supported by continued momentum in Darzalex and EPKINLY, while management raised 2026 revenue and operating-profit guidance. The fund believes the market undervalues Genmab's research and development capability, expanding commercial portfolio and deep oncology pipeline, providing scope for continued earnings growth and operating leverage.
“We believe the market undervalues Genmab’s R&D capacity, growing commercial portfolio and deep oncology pipeline.”